Literature DB >> 24695850

Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice.

Tomomi Toubai1, Guoqing Hou1, Nathan Mathewson1, Chen Liu2, Ying Wang1, Katherine Oravecz-Wilson1, Emily Cummings1, Corinne Rossi1, Rebecca Evers1, Yaping Sun1, Julia Wu1, Sung Won Choi3, Dexing Fang4, Pan Zheng5, Yang Liu5, Pavan Reddy1.   

Abstract

Activation of sialic-acid-binding immunoglobulin-like lectin-G (Siglec-G) by noninfectious damage-associated molecular patterns controls innate immune responses. However, whether it also regulates T-cell-mediated adaptive immune responses is not known. Graft-versus-host reaction is a robust adaptive immune response caused by allogeneic hematopoietic cell transplantation that have been activated by antigen-presenting cells (APCs) in the context of damaged host tissues following allogeneic hematopoietic cell transplantation. The role of infectious and noninfectious pattern recognition receptor-mediated activation in the induction and aggravation of graft-versus-host disease (GVHD) is being increasingly appreciated. But the role of pathways that control innate immune responses to noninfectious stimuli in modulating GVHD has heretofore not been recognized. We report that Siglec-G expression on host APCs, specifically on hematopoietic cells, negatively regulates GVHD in multiple clinically relevant murine models. Mechanistic studies with various relevant Siglec-G and CD24 knockout mice and chimeric animals, along with rescue experiments with novel CD24 fusion protein demonstrate that enhancing the interaction between Siglec-G on host APCs with CD24 on donor T cells attenuates GVHD. Taken together, our data demonstrate that Siglec-G-CD24 axis, controls the severity of GVHD and suggest that enhancing this interaction may represent a novel strategy for mitigating GVHD.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24695850      PMCID: PMC4041170          DOI: 10.1182/blood-2013-12-545335

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

Review 1.  Immune inhibitory receptors.

Authors:  J V Ravetch; L L Lanier
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

2.  Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines.

Authors:  G R Hill; J M Crawford; K R Cooke; Y S Brinson; L Pan; J L Ferrara
Journal:  Blood       Date:  1997-10-15       Impact factor: 22.113

3.  The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells.

Authors:  J Friederichs; Y Zeller; A Hafezi-Moghadam; H J Gröne; K Ley; P Altevogt
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

4.  Prevention of graft versus host disease by inactivation of host antigen-presenting cells.

Authors:  W D Shlomchik; M S Couzens; C B Tang; J McNiff; M E Robert; J Liu; M J Shlomchik; S G Emerson
Journal:  Science       Date:  1999-07-16       Impact factor: 47.728

5.  Altered erythrocytes and a leaky block in B-cell development in CD24/HSA-deficient mice.

Authors:  P J Nielsen; B Lorenz; A M Müller; R H Wenger; F Brombacher; M Simon; T von der Weid; W J Langhorne; H Mossmann; G Köhler
Journal:  Blood       Date:  1997-02-01       Impact factor: 22.113

6.  Heat shock protein 70: correlation of expression with degree of graft-versus-host response and clinical graft-versus-host disease.

Authors:  M Jarvis; M Marzolini; X N Wang; G Jackson; L Sviland; A M Dickinson
Journal:  Transplantation       Date:  2003-09-15       Impact factor: 4.939

7.  Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  G R Hill; K R Cooke; T Teshima; J M Crawford; J C Keith; Y S Brinson; D Bungard; J L Ferrara
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

8.  Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease.

Authors:  K R Cooke; G R Hill; J M Crawford; D Bungard; Y S Brinson; J Delmonte; J L Ferrara
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

9.  CD24 expression on T cells is required for optimal T cell proliferation in lymphopenic host.

Authors:  Ou Li; Pan Zheng; Yang Liu
Journal:  J Exp Med       Date:  2004-10-11       Impact factor: 14.307

10.  Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease.

Authors:  F P Nestel; K S Price; T A Seemayer; W S Lapp
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

View more
  34 in total

Review 1.  Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease.

Authors:  Tomomi Toubai; John Magenau
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

Review 2.  CD24: from a Hematopoietic Differentiation Antigen to a Genetic Risk Factor for Multiple Autoimmune Diseases.

Authors:  Yixin Tan; Ming Zhao; Bo Xiang; Christopher Chang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 3.  Siglec-mediated regulation of immune cell function in disease.

Authors:  Matthew S Macauley; Paul R Crocker; James C Paulson
Journal:  Nat Rev Immunol       Date:  2014-09-19       Impact factor: 53.106

Review 4.  Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.

Authors:  Robert Zeiser; Bruce R Blazar
Journal:  N Engl J Med       Date:  2017-11-30       Impact factor: 91.245

5.  IAPs protect host target tissues from graft-versus-host disease in mice.

Authors:  Tomomi Toubai; Corinne Rossi; Katherine Oravecz-Wilson; Chen Liu; Cynthia Zajac; Shin-Rong Julia Wu; Yaping Sun; Hideaki Fujiwara; Hiroya Tamaki; Daniel Peltier; Mary Riwes; Israel Henig; Stuart Brabbs; Colin S Duckett; Shaomeng Wang; Pavan Reddy
Journal:  Blood Adv       Date:  2017-08-16

6.  STAT3 Expression in Host Myeloid Cells Controls Graft-versus-Host Disease Severity.

Authors:  Evelyn C Nieves; Tomomi Toubai; Daniel C Peltier; Katherine Oravecz-Wilson; Chen Liu; Hiroya Tamaki; Yaping Sun; Pavan Reddy
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-08       Impact factor: 5.742

Review 7.  Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis.

Authors:  James Lm Ferrara; Christopher M Smith; Julia Sheets; Pavan Reddy; Jonathan S Serody
Journal:  J Clin Invest       Date:  2017-06-05       Impact factor: 14.808

Review 8.  Role of siglecs and related glycan-binding proteins in immune responses and immunoregulation.

Authors:  Bruce S Bochner; Nives Zimmermann
Journal:  J Allergy Clin Immunol       Date:  2015-01-13       Impact factor: 10.793

9.  Siglec-G represses DAMP-mediated effects on T cells.

Authors:  Tomomi Toubai; Corinne Rossi; Katherine Oravecz-Wilson; Cynthia Zajac; Chen Liu; Thomas Braun; Hideaki Fujiwara; Julia Wu; Yaping Sun; Stuart Brabbs; Hiroya Tamaki; John Magenau; Pang Zheng; Yang Liu; Pavan Reddy
Journal:  JCI Insight       Date:  2017-07-20

Review 10.  Next generation treatment of acute graft-versus-host disease.

Authors:  J Magenau; P Reddy
Journal:  Leukemia       Date:  2014-06-18       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.